在teprotumumab治疗后甲状腺眼病表型的转变
Julie M Shabto1, Shanlee Stevens, Celestine Gregerson
1Department of Ophthalmology, Irving Medical Center, Edward S. Harkness Eye Institute, Columbia University, New York City, New York, U.S.A.
Ophthalmic plastic and reconstructive surgery
|November 6, 2025
概括
甲状腺眼病的teprotumumab治疗导致患者的表型发生严重变化. 这一案例凸显了胰岛素类生长因子1 (IGF-1) 抑制对疾病表现的潜在影响.
科学领域:
- 眼科医生 眼科 眼科
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
背景情况:
- 甲状腺眼病 (TED) 是一种与格雷夫斯病相关的自身免疫性疾病.
- 德图穆马布是一种针对IGF-1受体的新型生物药物,用于治疗中度至重度TED.
- 在TED的表型变化可以发生,但治疗后显著的转变是不常见的.
研究的目的:
- 在teprotumumab治疗后报告甲状腺眼病表型变化的罕见病例.
- 研究IGF-1抑制在改变TED表型中的潜在作用.
主要方法:
- 一个35岁的女性患有格雷夫斯病和轻度TED病例报告.
- 在初始轻度症状时使用teprotumumab治疗.
- 在治疗后观察疾病进展和表型变化.
主要成果:
- 最初的轻度TED (I型) 随着单边的眼收缩转变为严重的TED (II型).
- 进展包括眼外肌肉扩大,双边亡和压缩性视神经病变.
- 严重的表型对类固醇无反应,需要手术减压.
结论:
- 采用teprotumumab治疗可能与甲状腺眼病的表型转变有关.
- 阻断IGF-1受体可能会影响TED的呈现和严重程度.
- 需要进一步的研究来了解teprotumumab对TED表型的长期影响.
相关概念视频
01:27Hyperthyroidism II: Pathophysiology
58
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
58
01:24Graves Disease II: Pathophysiology
59
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
59